Nexus装置主动脉弓腔内覆膜支架移植术后三年随访:前瞻性多中心研究结果
这项前瞻性多中心研究评估了单分支、双模块、即用型Nexus主动脉弓覆膜支架系统在高危患者中的3年结局,共纳入28例患者,1年和3年总生存率分别为89%和71%,1年和3年非计划再干预累积发生率分别为11%和29%,结论认为该单分支即用型Nexus系统在高危患者队列中3年随访提供有希望的临床和影像学结果。
要点
- Nexus单分支即用型主动脉弓覆膜支架在高危患者中3年总生存率为71%。
- 1年和3年非计划再干预累积发生率分别为11%和29%。
- 1至3年随访期间未报告卒中、截瘫、动脉瘤破裂、心肌梗死或新发主动脉瓣关闭不全。
核心结论
- 单分支即用型Nexus系统行主动脉弓腔内隔绝在高危患者队列中3年随访提供有希望的临床和影像学结果。
研究设计与样本
- 前瞻性多中心研究,纳入在5个中心接受Nexus治疗的患者,包括可行性临床研究或同情用药程序,共分析28例患者数据。
主要发现
- 总中位随访时间为1132天(四分位距:809-1537)。
- 1年和3年总生存率分别为89%和71%。
- 1年和3年非计划再干预累积发生率分别为11%和29%。
- 1至3年随访期间检测到1例Ib型(4%)、1例II型(4%)和2例III型(8%;位于Nexus远端与胸主动脉腔内修复(TEVAR)延伸段之间)内漏。
- 1至3年间无装置或操作相关死亡,未报告卒中、截瘫、动脉瘤破裂、心肌梗死或新发主动脉瓣关闭不全。
关键数值与推荐
- 主要终点为总生存率,次要终点包括操作相关非计划干预、卒中、截瘫和内漏的发生率。
- 临床和影像学随访在术后30天、6个月及此后每年进行至术后3年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Endovascular aortic arch stent grafting with branched devices has shown initial promising results. The aim of this prospective, multicentre study was to evaluate 3-year outcomes of aortic arch stent grafting with NEXUS® Aortic Arch Stent Graft System (Nexus), a single-branch, bi-modular, off-the-shelf aortic arch stent graft system in high-risk patients. METHODS: Patients treated with Nexus, either under the feasibility clinical study or as compassionate use procedures in 5 centres, were included in this study. The primary end point was overall survival. The secondary end points included the incidence of procedure-related unplanned intervention, stroke, paraplegia and endoleak. Clinical and radiologic follow-up was performed at each study site at 30 days, 6 months and on a yearly basis thereafter up to 3 years postoperatively. RESULTS: We analysed data from a total of 28 patients. The overall median follow-up was 1132 (interquartile range: 809-1537). There were no device or procedure-related deaths between 1 and 3 years. Overall survival at 1 and 3 years was 89% and 71%, respectively. The cumulative incidence of unplanned reintervention at 1 and 3 years was 11% and 29%, respectively. There were no reports of stroke, paraplegia, aneurysm rupture, myocardial infarction or new aortic valve insufficiency. In this study's 1-3 year follow-up period, 1 type Ib (4%), 1 type II (4%) and 2 type III (8%; between Nexus' distal end and Thoracic endovascular aortic repair (TEVAR) extensions) endoleak were detected. CONCLUSIONS: Endovascular aortic arch exclusion with the single-branch, off-the-shelf Nexus system provides promising clinical and radiologic results at 3-year follow-up in a high-risk patient cohort.
引用
- D'Onofrio A, Lachat M, Mangialardi N, et al. Three-year follow-up of aortic arch endovascular stent grafting with the Nexus device: results from a prospective multicentre study. Eur J Cardiothorac Surg. 2022. PMID: 36484696. doi:10.1093/ejcts/ezac561
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。